Analysis BioNTech’s Pipeline Grows Faster Than Its Stock, Leaving a 36% Analyst Upside on the Table
BioNTech’s transformation from a pandemic-era vaccine champion into a fully-fledged oncology powerhouse is proceeding at full throttle. The pipeline is expanding, the cash pile is massive, and a $1 billion...